A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma

Clinical trial NCT02434354 · COMPLETED

Trial details

NCT number: NCT02434354
Sponsor: Abramson Cancer Center at Penn Medicine
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Malignant Melanoma

Start date: 2015-04-01
Primary completion: 2019-07-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.